Literature DB >> 15577675

Serous endometrial cancers that mimic endometrioid adenocarcinomas: a clinicopathologic and immunohistochemical study of a group of problematic cases.

Farbod Darvishian1, Amanda J Hummer, Howard T Thaler, Rohit Bhargava, Irina Linkov, Marina Asher, Robert A Soslow.   

Abstract

BACKGROUND: Uterine serous carcinomas (USCs) can exhibit an architecturally well-differentiated tubuloglandular morphology with or without an accompanying papillary growth pattern. These features make it difficult to distinguish USCs from endometrial endometrioid carcinomas (EECs). Given the aggressive behavior of USC, compared with EEC, and differences in management, it is important to correctly classify endometrial carcinomas that exhibit a tubuloglandular architecture with high nuclear grade. We sought an immunohistochemical panel to minimize subjectivity in the distinction of USC from EEC.
MATERIALS AND METHODS: We identified 8 problematic endometrial cancers, exhibiting a tubuloglandular growth pattern and high nuclear grade, whose classification as EEC or USC was debated or resulted in disagreement. We selected 13 cases of International Federation of Gynecology and Obstetrics (FIGO) grade 2 EEC and 16 cases of USC as controls. An immunohistochemical panel, including p53, beta-catenin, cyclin D1, estrogen receptor (ER), progesterone receptor (PR), and PTEN, was evaluated.
RESULTS: As a group, the clinical features and immunoprofile of the study cases resembled those of the serous controls. The study cases expressed p53, beta-catenin, cyclin D1, and ER and PR, and showed loss of PTEN in 75%, 12.5%, 0%, 37.5%, 37.5%, and 12.5% of cases, respectively. p53, beta-catenin, cyclin D1, ER and PR expression, and PTEN loss were seen in 87.5%, 0%, 19%, 31%, 12%, and 0% of the serous controls and in 7%, 70%, 54%, 92%, 92%, and 61.5% of the endometrioid controls, respectively. The combination of lack of p53 expression, positive PR expression, and loss of PTEN best distinguished between EEC and USC using discriminant analysis (multivariate P = 0.008, <0.001, and 0.05, respectively).
CONCLUSION: In endometrial carcinomas exhibiting high nuclear grade and low architectural grade, using a panel of immunohistochemical stains may facilitate the distinction of USC from EEC. Our clinical and immunohistochemical data also support the concept that there is a group of endometrial adenocarcinomas composed of tubular glands that are indeed serous carcinomas.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15577675     DOI: 10.1097/00000478-200412000-00004

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  17 in total

Review 1.  The emerging genomic landscape of endometrial cancer.

Authors:  Matthieu Le Gallo; Daphne W Bell
Journal:  Clin Chem       Date:  2013-10-29       Impact factor: 8.327

Review 2.  Practical issues in the diagnosis of serous carcinoma of the endometrium.

Authors:  Sonia Gatius; Xavier Matias-Guiu
Journal:  Mod Pathol       Date:  2016-01       Impact factor: 7.842

3.  A case of minimal uterine serous carcinoma with distant lymph node metastasis without peritoneal dissemination.

Authors:  Kouichiro Kawano; Kimio Ushijima; Masato Yokomine; Akimasa Fukui; Morio Ijichi; Toshiharu Kamura
Journal:  J Gynecol Oncol       Date:  2011-03-31       Impact factor: 4.401

4.  Use of mutation profiles to refine the classification of endometrial carcinomas.

Authors:  Melissa K McConechy; Jiarui Ding; Maggie Cu Cheang; Kimberly Wiegand; Janine Senz; Alicia Tone; Winnie Yang; Leah Prentice; Kane Tse; Thomas Zeng; Helen McDonald; Amy P Schmidt; David G Mutch; Jessica N McAlpine; Martin Hirst; Sohrab P Shah; Cheng-Han Lee; Paul J Goodfellow; C Blake Gilks; David G Huntsman
Journal:  J Pathol       Date:  2012-07-18       Impact factor: 7.996

5.  Insights into endometrial serous carcinogenesis and progression.

Authors:  Oluwole Fadare; Wenxin Zheng
Journal:  Int J Clin Exp Pathol       Date:  2009-01-10

6.  Molecular Analysis of Mixed Endometrial Carcinomas Shows Clonality in Most Cases.

Authors:  Martin Köbel; Bo Meng; Lien N Hoang; Noorah Almadani; Xiaodong Li; Robert A Soslow; C Blake Gilks; Cheng-Han Lee
Journal:  Am J Surg Pathol       Date:  2016-02       Impact factor: 6.394

7.  Endometrial cancer: what is new in adjuvant and molecularly targeted therapy?

Authors:  Flora Zagouri; George Bozas; Eftichia Kafantari; Marinos Tsiatas; Nikitas Nikitas; Meletios-A Dimopoulos; Christos A Papadimitriou
Journal:  Obstet Gynecol Int       Date:  2010-02-02

Review 8.  [Pitfalls in the histopathological diagnostics of endometrial carcinoma and its precursors : Clinically relevant differential diagnoses, avoidance of false positive diagnoses].

Authors:  F Kommoss; S F Lax
Journal:  Pathologe       Date:  2016-11       Impact factor: 1.011

9.  Are the uterine serous carcinomas underdiagnosed? Histomorphologic and immunohistochemical correlates and clinical follow up in high-grade endometrial carcinomas initially diagnosed as high-grade endometrioid carcinoma.

Authors:  Shaomin Hu; Jeff L Hinson; Rahul Matnani; Michael L Cibull; Rouzan G Karabakhtsian
Journal:  Mod Pathol       Date:  2017-10-06       Impact factor: 7.842

Review 10.  Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer.

Authors:  J Julie Kim; Takeshi Kurita; Serdar E Bulun
Journal:  Endocr Rev       Date:  2013-01-09       Impact factor: 19.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.